Literature DB >> 27797815

Piperacillin-induced mild haemolytic anaemia in a 44-year-old patient with cystic fibrosis.

Carolin Meinus1, Carsten Schwarz1, Beate Mayer2, J F Roehmel1.   

Abstract

Piperacillin-tazobactam is an antipseudomonal antibiotic frequently used in patients with cystic fibrosis (CF) to treat pulmonary exacerbations. Drug-induced immune haemolytic anaemia is a rare complication during treatment with piperacillin. So far, piperacillin-induced immune haemolytic anaemia (PIHA) is regarded as an acute and severe haemolytic anaemia resulting into life-threatening events. Here we report on a patient with mild PIHA, which did not result in any clinical symptoms or necessity for treatment. To the best of our knowledge, this is the first case report of PIHA without an acute severe haemolytic anaemia. Further research is needed to clarify if this case is a solitary clinical manifestation of PIHA or if mild clinical courses of PIHA might be under-reported. Cases of PIHA have been largely reported in patients with CF. This unequal distribution maybe due to the frequent administration of piperacillin for pulmonary exacerbation in patients with CF or due to CF-related cofactors of yet unknown aetiology. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27797815      PMCID: PMC5093803          DOI: 10.1136/bcr-2016-216937

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  16 in total

1.  Transfusion medicine illustrated. Profound piperacillin-mediated drug-induced immune hemolysis in a patient with cystic fibrosis.

Authors:  Eric Gehrie; Anne T Neff; Kristen K Ciombor; Nadine Harris; Adam C Seegmiller; Pampee P Young
Journal:  Transfusion       Date:  2011-10-27       Impact factor: 3.157

Review 2.  Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007.

Authors:  George Garratty; Patricia A Arndt
Journal:  Immunohematology       Date:  2014

3.  Immune-mediated severe hemolytic crisis with a hemoglobin level of 1.6 g/dl caused by anti-piperacillin antibodies in a patient with cystic fibrosis.

Authors:  S Kunzmann; W Thomas; B Mayer; S Kuhn; H Hebestreit
Journal:  Infection       Date:  2010-03-05       Impact factor: 3.553

4.  Hemolytic anemia as a result of piperacillin/tazobactam administration: a case report and discussion of pathophysiology.

Authors:  Richard C Zanetti; Abhik K Biswas
Journal:  Mil Med       Date:  2013-09       Impact factor: 1.437

5.  Life-threatening piperacillin-induced immune haemolysis in a patient with cystic fibrosis.

Authors:  Paul Ellis Marik; Parth Parekh
Journal:  BMJ Case Rep       Date:  2013-01-04

Review 6.  Immune hemolytic anemia caused by drugs.

Authors:  George Garratty
Journal:  Expert Opin Drug Saf       Date:  2012-04-16       Impact factor: 4.250

Review 7.  Piperacillin-induced immune hemolysis: new cases and a concise review of the literature.

Authors:  Beate Mayer; Salih Yürek; Abdulgabar Salama
Journal:  Transfusion       Date:  2009-12-29       Impact factor: 3.157

8.  Piperacillin-induced immune hemolytic anemia in an adult with cystic fibrosis.

Authors:  Mahesh Bandara; David B Seder; George Garratty; Regina M Leger; Jonathan B Zuckerman
Journal:  Case Rep Med       Date:  2010-06-02

9.  Piperacillin-induced anemia and leukopenia.

Authors:  R B Bressler; D P Huston
Journal:  South Med J       Date:  1986-02       Impact factor: 0.954

10.  Piperacillin-induced immune hemolysis presenting with tachycardia and cardiac arrest.

Authors:  Ghan-Shyam Lohiya; Lilia Tan-Figueroa; Vamsi Krishna
Journal:  Case Rep Med       Date:  2011-12-22
View more
  1 in total

1.  Severe piperacillin-tazobactam-induced hemolysis in a cystic fibrosis patient.

Authors:  Andrew D Kerkhoff; Lauren Patrick; Patricia Cornett; Mary-Ellen Kleinhenz; Sam Brondfield
Journal:  Clin Case Rep       Date:  2017-11-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.